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Abstract
Substantial progress has been made over the past three decades in understanding breast 
cancer (BC) molecular biology, genomics, and targeted therapy. The recent comprehen-
sive molecular and pathological diversity observed in BC patients indicates that BC is 
not a homogeneous disease; It may be appropriately defined as a myriad of diseases. The 
explosion of molecular information in the past 10 years has led to a better understanding 
of the biologic diversity of breast cancers (BCs), and clues to the different etiologic path-
ways to BC development. It will be useful to study the epigenetics of BC cells and define 
the mechanisms of both genetic and epigenetic driving alterations beside the mutations. 
Identifying the oncogenes and tumor suppressor genes is the purpose cancer diagnostics 
and therapeutics. Oncogenes as well as novel ones involved in the significantly altered 
regions would enable researchers to identify new causes and molecular pathways that 
may be targeted at BC treatment. Our main goal is to provide comprehensive understand-
ing of underlying molecular mechanisms and hallmarks of BC, focusing on the identifi-
cation of fingerprints and novel molecular targets that will greatly improve the cancer 
predictive, prognostic, and diagnostic biomarkers and, in addition, the possible targets 
for novel therapies.
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1. Introduction
Cancers, including breast cancer, are generally thought to develop from a single cell in which 
mutations and/or epigenetic events have modified the function of genes responsible for cellular 
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growth regulation. These events establish the malignant phenotype, and subsequent 
 molecular events may lead to the emergence of malignant subclones with enhanced growth 
and metastatic potential [1]. Cancer cells, replicating inappropriately, eventually interfere 
with normal tissue and organism functions, cause morbidity and may ultimately prove fatal 
in the absence of effective therapy. The rate of growth of tumours including, breast tumours, 
is determined by a balance between cell proliferation and cell death; if the rate of prolifera-
tion exceeds that of death, tumour growth will occur. Not surprisingly, many of the genes 
involved in neoplasia turn out to be concerned with control of cell death, as well as with 
control of cell proliferation [2].
The genes involved in neoplasia are usually classified as oncogenes or tumour suppressor 
genes, depending on whether the affected gene has gained or lost function in its mutated 
form. In keeping with this model, breast cancer is the result of imbalance in complex regula-
tory controls of cellular development and growth. Genetic abnormalities detected in breast 
carcinomas include mutation and amplification of oncogenes, mutation of tumour suppressor 
genes, and loss of heterozygosity at certain chromosomal loci. Sex hormones, growth factors, 
oncogenes, and tumour suppressor genes all regulate gene expression and thereby influence 
growth and function of breast epithelial cells. Influences favouring cell proliferation or inhib-
iting cell death may promote tumour progression [3].
Breast carcinoma is phenotypically complex: carcinoma in situ and invasive carcinoma may 
coexist, as mixed histological types of invasive carcinoma, and infiltrating ductal carcino-
mas often contain areas with different grades of disease. This morphological heterogeneity 
mirrors molecular heterogeneity, as well as morphologically similar tumours may differ in 
genetic and metabolic processes, and specific genetic abnormalities may influence clinical 
outcome [4, 5].
Prognosis and likely responses to therapy are clinically important in breast cancer and many 
variables have been evaluated. Classical morphological variables including histological type, 
tumour size, grade, lymph node status, and whether or not there is blood or lymphatic vascu-
lar invasion remain the strongest predictors of tumour behaviour. Attempts to evaluate breast 
tumour prognosis from individual or combined expression of variables such as oestrogen and 
progesterone receptor, cell proliferation index, S-phase fraction, DNA ploidy, growth factors 
and their receptors, oncogenes, tumour suppressor genes, proteases, components of the plas-
minogen system, and cell cycle regulators have yet to match the clinical utility of the classical 
morphological factors [6].
The chief forms of carcinoma of the breast are breast cancers that are classified into those 
that have not penetrated the limiting basement membrane (noninvasive) and those that have 
(invasive). The WHO current classification [7] is illustrated in Figure 1.
Breast cancer is the most commonly diagnosed cancer in women with an increased incidence 
of 14.1 million new cases in year 2012 and high mortality rate about 8.2 million deaths all over 
the world [8]. The incidence rate is expected to increase by year 2020 to reach about double 
the rate in 2012 [9]. Young women aged 20–59 years are expected to suffer from breast cancer 
with increased rate of death from cancer among their age group [10].
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2. Breast cancer risk factors
The transformation of the normal epithelium into carcinoma is a multistep process. Genetic 
background and environmental and dietary factors have a role in breast cancer development. 
In the normal breast tissue, there is a balance between negative and positive growth factors, so 
to develop, breast cancer requires loss or gain in some functions [5]. The following factors are 
thought to be related to breast cancer development:
2.1. Age
The increased incidence of breast cancer with age may reflect the accumulation of somatic 
mutation. Early menarche and late menopause prolong the exposure to ovarian hormones 
and are associated with a higher incidence of breast cancer. There is some evidence that breast 
cancer in younger women is more aggressive than in older women, consistent with a more 
rapidly evolving disease declaring itself sooner clinically [11].
2.2. Genetic factors
Complex acquired genetic alterations are considered to cause breast cancer, and genetic abnor-
malities in the premalignant and malignant breast epithelium are likely to have a causal role [12]. 
Figure 1. Classification of cancer breast.
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That most breast cancers are due to acquired mutations is implied by the fact that only 5% of 
breast cancer patients have a strong family history indicating inheritance of tumour-promoting 
mutations in the germ line. Inherited early-onset breast cancer is largely attributable to two genes, 
BRCA1 and BRCA2. Li-Fraumeni syndrome, ataxia telangiectasia, and Cowden’s disease are also 
associated with increased risk of breast cancer [13].
2.3. Hormonal status
Breast cancer risk appears to increase with exposure to mammotropic hormones, mainly oestro-
gen, progesterone, prolactin, and insulin-like growth factor 1 during adolescence and adult life. 
This may be explained by an increased epithelial cell population at risk during the preinitiation 
stage, affecting clonal expansion and modulating growth enhancement in subclinical tumours. 
Estrogen is a dominant influence on breast growth, but its role depends on oestrogen receptor 
(ER) expression in the target tissues. Recently, it has been suggested that overexpression of 
oestrogen receptors in the normal breast epithelium increases breast cancer risk in women [5].
2.4. Previous benign breast disease
Clear evidence exists that certain subtypes of benign breast disease are associated with breast 
cancer. In benign breast neoplasia, inactivation of tumour suppressor genes may occur and 
loss of heterozygosity is also reported. Ductal and lobular carcinomas in situ have a partly 
malignant morphological phenotype, lacking the ability to invade and metastasize, but are 
associated with elevated invasive cancer risk. Other lesions associated with abnormal cell 
proliferation are also associated with more modestly elevated cancer risk, notably the atypical 
hyperplasia (ductal and lobular) and florid hyperplasia of usual type (that is, without atypia). 
Frequent coexistence of premalignant lesions with invasive breast cancer is consistent with 
progression from these lesions to cancer, but there are many controversies in this area, and 
clonal relationships are not always clear [4].
3. Carcinogenesis and pathogenesis of breast cancer
The prognosis of breast cancer is variable and affected by the heterogeneity of breast cancer, 
different pattern of breast subtypes, and aggressive genetic behaviour. All these factors may 
be associated with worsen patient outcome if accumulated with effect of hormonal status, 
and bilateral oophorectomy may improve prognosis in breast cancer. Depending upon these 
data, reduced breast cancer mortality is achieved, but still breast cancer is the most prevalent 
cancer in young women [14]. Aggressive behaviour of breast cancer is due to collision of bio-
logically active tumour and genetic abnormalities, but targeted interventions may improve 
the survival rate and patient outcome [3].
Estrogen has a crucial role in many tumours including ovaries, endometrium, and mam-
mary gland cancers and also prostate cancer. Estrogen is linked to enhanced proliferation, 
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decreased apoptosis, and DNA damage in breast cancer. Several experiments on animals have 
demonstrated that estradiol administration increased the risk of breast cancer, while antioes-
trogen agents had an opposite effect. Response of breast cancer to antioestrogen therapy after 
the confirmed presence of high percentage of hormonal receptors is defined as hormonal-
dependent breast cancer [15].
The presented framework of circulating tumour cell (CTC) biology and classification of CTC 
assays might help to structure this dynamic field of translational cancer research. Better 
insights into the biology of CTCs will further improve CTC assay development [1, 16]. Based 
on the theories proposed that tumour cells are heterogeneous and breast cancer is the most 
famous heterogeneous tumour. Therefore, CTC belonging to breast cancer requires special 
detection approach. Specific profile for CTCs could be targeted for successful detection of 
complex aggressive breast cancer [17].
Tumorigeneses are postulated by many research works due to multiple steps and may 
start as chronic disease and processed to cancer. Intervention and prevention of these steps 
before cancer emerge is a good chance for reducing breast cancer risk. Adjuvant therapies as 
tamoxifen are effective and safe in significantly reducing and preventing molecular changes 
that lead to cancer. Those targeted hormonal therapies are very important to stop invasion 
and metastasis of tumour cells. Blocking DNA mutation is also initiated by using micronu-
trients and gene therapy to target abnormal pathways that claimed to had a role in carcino-
genesis [5].
4. Gene expression profiling of breast cancer
Management of breast cancer depends on clinicopathologic parameters including age, stage, 
hormonal status, and Ki67 status. Alteration of molecular genetic character including altera-
tions at DNA, RNA, and the protein functional changes contributes to oncogenesis. However, 
epigenetic changes and regulatory or transcriptional molecules as snRNA, siRNA, and miRNA 
may be other significantly contributing molecules as well. Successful therapy depends on 
hormone receptor and human epidermal growth factor receptor 2 (Her2) pathway by analys-
ing their immunohistochemical expression. Failure to respond to the traditional treatment 
increases morbidity and mortality, and so further discovery of molecular variation in indi-
viduals could help in classifying breast cancer subtypes. Clonal analysis of different breast 
cancer types to understand molecular modifications and genetic expression help in producing 
full accurate histopathological diagnosis [18].
In the past decade, where breast cancer is clustered in families due to a common genetic fac-
tor BRCA1 or BRCA2 mutation, environmental factors shared between relatives may also be 
relevant. There has been progress in development of new therapeutic approaches that target 
these BRCA1 and BRCA2 cancer susceptibility genes, which led to loss of functional muta-
tions in either BRCA1 or BRCA2 [19].
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Recent delivery of nucleic acid mimics and therapeutic-based miRNA could be used for nano-
delivery of target therapy to specific site. In addition, miRNA were recently studied as biological 
biomarkers in breast cancer, specifically for diagnosis, predicting cancer behavior and outcome [20].
5. Hormone receptors
The breast epithelium undergoes hyperplasia or involution in response to hormone supple-
mentation or withdrawal, and oestrogen and progesterone receptors in the breast tissue medi-
ate proliferative effects. Certain genetic alterations (alteration to the DNA-binding domain) 
are associated with high overall tumour grade and lack of steroid hormone receptors; an 
inverse correlation between both receptor expression and nuclear anaplasia also indicates a 
relation with cellular differentiation. Steroid hormone receptor expression in breast neopla-
sia has prognostic value. Moreover, there is an independent correlation between oestrogen 
and progesterone receptor status in breast cancer and tumour progression [21, 22].
5.1. Oestrogen receptors (ER) and progesterone receptors (PR)
Estrogen and progesterone receptors are unique signature to define personalized therapy 
of breast cancer, and their genetic expression may contribute to breast cancer management 
through using antioestrogen-targeted therapy. If mutated DNA is spilled from dying cancerous 
cells into the blood stream, it will become habitant into lymphatic or blood channels and so-
called circulating tumor cells. Circulating tumour cells are capable of stimulating other tissues 
towards continuous proliferation and could be a tool to measure tumour power and ability to 
enhance metastases [18]. Further research is mandatory to identify those patients at high risk 
of breast cancer and to understand method of optimization of circulating tumour cell measure-
ment. In addition, there is progressive need for clinical evolution of new agents and targeted 
therapy, especially to whom with BRCA positive and triple-negative breast cancer patients [23].
5.2. HER2
The HER2/neu oncogene is located on chromosome 17 at band q 21. It is related to the cerbB-1 
(EGFR, HER1) gene which encodes the epidermal growth factor receptor. In addition to its 
function as a growth factor receptor, it is involved in the regulation of cellular differentiation, 
adhesion, and motility. When HER2/neu gene is amplified and as a result HER2/neu protein is 
substantially overexpressed, it is very likely that this plays a role in tumour development and 
progression [3]. HER2 amplification and overexpression may provide prognostic and therapeu-
tic information in breast cancer and predict resistance to adjuvant therapy. Amplification of this 
gene is associated with rapid proliferation, shorter disease-free survival, and poorer prognosis 
in both node-negative and node-positive ductal breast carcinomas and a risk factor for the devel-
opment of distant metastases. It has true independent prognostic significance but is associated 
with hormone-independent tumours. Progress of personalized medicine does well for patients 
to depend on Herceptin treatment. The ultimate goal is to understand cancer behaviour and 
improve patient survival rate and treatment outcome [6]. Some of the currently utilized cancer 
biomarkers for breast cancer and their clinical significance are illustrated in Table 1.
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6. Molecular targeting therapy and personalized  
medicine in breast cancer
Breast cancer is a heterogeneous disease that encompasses subtypes characterized by specific 
molecular biomarkers: oestrogen receptor (ER) positive, human epidermal growth factor 
receptor 2 (HER2) positive, and triple-negative (TNBC) which are ER, progesterone recep-
tor (PR), and HER2 negative breast cancers [5]. Perfect diagnosis and detection of molecular 
abnormalities help in improvement of personalized therapies to block these mutations by tar-
geted therapy. The best example is using HER2 expression by immunohistochemistry or gene 
amplification to develop accurate therapy with trastuzumab [24]. Trastuzumab is targeted 
against domain IV of HER2 [25], while pertuzumab (Perjeta) is targeted monoclonal antibody 
against the ligand domain II of HER2. Lapatinib is dual targeting therapy for both HER2 and 
epidermal growth factor receptor (EGFR 1), specifically against its intracellular domain; it 
acts as tyrosine kinase inhibitor (TKI) as well [26]. Patients on combined lapatinib and trastu-
zumab have better outcome and survival; such therapy could be assessed with HER2 expres-
sion [27]. In fact, combining the HER2 targeting therapies as a neoadjuvant or for metastatic 
late stage, as trastuzumab and lapatinib or pertuzumab, will significantly improve patient’s 
outcome in comparison with single anti-HER2 therapy [28–30]. Using combined and syner-
gistically acting therapy on the same target (HER2) would achieve better response because 
of the concomitant action on same receptor against two different epitopes, in addition to the 
likely deaddiction effect of target that may involve stimulation of the immune system [31].
Biomarker Clinical utility References
ER ER positivity indicates better prognosis in breast cancer patients who have better survival 
than ER-negative breast cancer patients
[55, 56]
Predict responsiveness to tamoxifen as when highly expressed, it predicts better response  
to tamoxifen therapy particularly in node-negative patients
[56]
PR Prognostic marker indicating better survival when positively expressed (PR +ve) [55]
High expression of PR predicts beneficial response to tamoxifen chemotherapy [57]
HER2/neu Prognostic marker for worse prognosis in patients with HER2/neu-positive  
tumours as they have more aggressive breast cancers
[58]
Predictor marker for the response to therapy with trastuzumab [59]
BRCA1 Prognostic marker for poor prognosis. High expression of BRCA1 indicates worse prognosis [60]
If highly expressed, BRCA1 can predict response to chemotherapy in breast cancer patients [61]
MammaPrint Prognosticator in a heterogeneous population for stratification of breast cancer patients  
into good or poor prognosis, it is a 70-gene assay
[38]
Oncotype DX A 21-gene multiplex prognostic assay used for determination of recurrence score. [62, 63]
Isoforms Akt 
kinase
Akt kinase isoforms and activity are predictive markers to suggest the most likely  
response to trastuzumab therapy in HER2-neu-positive patients of breast cancer
[64]
Table 1. Currently utilized cancer biomarkers for breast cancer and their clinical significance.
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6.1. mechanistic target of rapamycin (mTOR)/PI3K/Akt-pathway inhibitors
Preclinical studies of the effects of AZD2014 in breast cancer are promising steps to confirm 
anti-proliferative role of mTOR signalling. Targeting mTOR pathway could suppress the 
development and progression of cancer, specifically gastrointestinal malignancies and breast 
cancer. The functions of mTOR pathway are mainly targeted for growth signaling, nutrient 
status, and metabolism with recent undiscovered impact in obesity development [23].
6.2. Therapeutic cancer vaccine
The monoclonal antibody drugs encourage T cells to detect and destroy cancer and increase 
the ability of the immune system to respond to tumours. Application of therapeutic can-
cer vaccine stimulates tumour antigen aiming at activation of tumour-specific T cells [32]. 
Therapeutic cancer vaccines require the selection of appropriate antigens that are not prone 
to central immunological tolerance induction in the thymus. Each type of cancer has its own 
particular immune-suppressive mechanisms guided by information of the immune memory. 
Selection of the best vaccine and its antigen delivery points should take place and be applied 
in treatment properly [33]. Breast cancer has the advantage of being based on huge antigen 
pool for an individual tumour, thus using tumor based-vaccines in breast cancer stimulate the 
activation of polyclonal immune responses. However, tolerance could occur to the immune 
system for expression of these antibodies. Co-stimulation and sensitization of the immune 
molecules will deliver all signals needed for activating T cells under the effect of antigen-spe-
cific immune response. Cytokines in breast cancer could be an ideal example of the immune 
costimulatory molecules [34].
7. “Omics” and promising biomarkers in breast cancer
Recently, with the merging of “omic” technologies such as genomics, proteomics, metabolo-
mics, transcriptomics, etc., a great advancement has been achieved in the field of cancer biol-
ogy with better understanding of carcinogenesis, cancer progression, metastasis, and target 
therapy [35]. Microarray, mass spectrometry, and sequencing techniques provide evolution-
ary era for promising cancer biomarkers [36]. Transcriptional profiling has been reported as a 
valuable tool for classification and determination of prognosis in patients of breast cancer [37, 
38]. Apart from diagnosis, prediction of response to therapy, and prediction of breast cancer 
patients’ outcomes, biomarkers may estimate risk assessment of getting cancer [39]. Genetic 
alterations in breast cancer or methylation of promoters of cancer-specific or associated genes 
will definitely linked to altered expression of certain proteins and may be used as emerging 
cancer biomarkers [40].
7.1. Genomic biomarkers: MammaPrint and Oncotype DX
MammaPrint is one of the emerging genomic assays that have been reported as prognostic 
biomarker, MammaPrint assay analyses 70 genes’ expression signatures, and it is used to strat-
ify patients into good or poor risk groups for recurrence [41]. Another example of promising 
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genomic markers is the 21-gene signature assessing test, Oncotype DX. It is a quantitative real-
time qRT-PCR-based assay, and both assays may provide physicians with very effective prog-
nostic information and consequently would help in selecting early-stage hormone responsive 
breast cancer patients who will have a likelihood of disease recurrence [38]. Signatures for 
both assays include genes as ER, HER2, PR-regulated transcripts and proliferation-linked 
genes that mainly have been utilized as a very effective tool for assessing the probability of 
recurrence as well as for classifying patients accordingly into high-, intermediate- or low-risk 
groups for recurrence. In addition, Oncotype DX assay may be used for assessing response to 
tamoxifen therapy [42].
7.2. Proteomics
Proteomic approach has been investigated through mass spectrometry, two-dimensional gel 
electrophoresis, and other strategies and successfully has identified promising markers for 
early diagnosis of ovarian cancer [43, 44]. In spite of being invalidated, their results have 
paved the path for applying the proteomic approach, via mass spectrometry, for identification 
of other biomarkers in serum in breast cancer [45] and nipple aspirate as well [46]. Moreover, 
a panel of proteins has also been identified by high-throughput antibody arrays’ technique, 
and their levels were significantly increasing in malignant breast tissue when compared to 
normal tissue. Such panel included p53, MAP kinase 7, and casein kinase Ie and annexin [47]. 
In fact, recent proteomics techniques such as nano-techniques are evolutionally emerging and 
promising to overcome few limitations of the conventional techniques for identification of 
potential biomarkers for early detection of cancer; thus, these techniques have to be applied 
on larger scale of cancer patients and, more importantly, with standardized protocols in order 
to validate the potentially valuable biomarkers [48].
7.3. DNA methylation
DNA methylation is an example of DNA modification that could be detected and linked with 
the unique identity of that gene; thus, DNA methylation patterns differ between normal and 
tumour tissues, and hence, targeting candidate genes could be used to identify and detect can-
cer cells in the blood or body fluid [49]. Identification of DNA methylation mapping and assays 
has been applied to nipple aspirate as well for detection of cancer cells at early stage of breast 
cancer [50]. DNA methylation assessment has been investigated as a prognostic marker for 
breast cancer in serum, and it was reported that methylation of adenomatous polyposis coli 
(APC) gene and Ras association domain family 1 isoform A was significantly linked and inde-
pendently associated with poor outcome in breast cancer patients [51].
7.4. Circulating tumour cells (CTCs)
Circulating tumour cells (CTCs) are detached or disseminated cells from solid tumours or their 
metastasis into circulation. It has been firstly detected in the bone marrow, called disseminated 
tumour cell (DTC) patients with early-stage breast cancer [52]. Once CTCs dislodged from 
cancerous tissues into circulation, they retain the proliferating capacity and ability to settle 
in other tissues. CTCs have the capability to proliferate and eventually forming  metastasis. 
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Hence, CTC could be a predictor marker for invasion and metastases [18]. Recently, CTCs were 
considered a dynamic prognostic marker whether in early- or late-metastasizing breast cancer 
cases [53]. Evaluation of CTCs might contribute for efficient therapy monitoring; in addition, 
expression profiles of CTCs may predict the likely responses to treatment. As well, assessment 
of the molecular features of them may be a pivotal step for the optimization of therapy [54].
8. Conclusion and prospective
Breast cancer with its heterogeneous nature and complex behaviour in great needs requires 
potential biomarkers to improve screening, diagnosis, classification, prognosis, and prediction 
to therapies. Understanding biology of breast tumour cell, host immune defences, and the 
tumour microenvironment may allow early detection and recurrence in breast cancer patients.
Breast cancer patients, clinician, pharmaceutical companies, and targeted therapy developer in 
great needs for flexible, simple, and inexpensive tests with sharp accurate comprehensive diag-
nosis. The identified molecular aberrations could be arrested and held up by the correspond-
ing targeted compounds, which are best exemplified by detection of HER2neu expression in 
breast cancer by immunohistochemistry and gene amplification tests for accurate treatment 
with trastuzumab. Molecular fingerprint for breast cancer generated to help medical practitio-
ner and healthcare providers to focus on patient’s prognosis and adopted the preferred best 
therapeutic option. Designation of distinctive incompatible genetic markers enhances shrink-
age of toxic side effect from overuse of therapies and exaggerated gains to patients.
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